Instituut voor Neuropathische Pijn

Home

AZD 2066 from AstraZeneca for neuropathic pain

AZD 2066 from AstraZeneca in phase II development for neuropathic pain. Most probably it is a negative allosteric modulators of mGluR5 receptor. It might be discontinued, as there is only one trial reported to be finalized in 2008: AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers. A report in pubmed could not be identified.

From the Centre for the study and treatment of Neuropathic Pain and Neuropathy in Soest, the Netherlands

This site helps patients and treating physicians, neurologists, anesthesiologists and other pain specialists to find the best and most up to date research findings related to neuropathy and neuropathic pain and the treatment thereof.

In our centre we are specialised in treating patients suffering from neuropathic pain and neuropathy following an Integrated Medicine concept. Part of our activities are within the field of consultation. We assist pharmaceutical companies in R&D strategies related to finding new drugs to treat neuropathic pain and neuropathy.

April 2010, Jan M. Keppel Hesselink, MD, PhD